SCHEMBL5658375

SCHEMBL5658375

CCN(CC)S(=O)(=O)c1ccc(C(=O)NCc2ccc(NC3=NCCN3)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.62
SMN1; SMN2 Q16637 4/20 0.54
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
NPSR1 Q6W5P4 2/20 0.52
RAB9A P51151 2/20 0.52
MAPK1 P28482 1/20 0.52
NAMPT P43490 1/20 0.51
LMNA P02545 3/20 0.51
MAPT P10636 1/20 0.51
ADRA2A P08913 2/20 0.50
ADRA2B P18089 2/20 0.50
ADRA2C P18825 2/20 0.50
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
THRB P10828 1/20 0.49
PPARG P37231 1/20 0.49
NCOA2 Q15596 1/20 0.49
NCOA1 Q15788 1/20 0.49
NCOA3 Q9Y6Q9 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5654940 0.90 ALDH1A1 (0.58) ALDH1A1MEN1KMT2ANPSR1MAPK1
SCHEMBL5666757 0.88 EPHX2 (0.55) ADRA2AADRA2BADRA2CMLLT1PTGIR
SCHEMBL5658534 0.86 ADRA2A (0.50) ALDH1A1MEN1KMT2ANAMPTLMNA
SCHEMBL5658627 0.85 ADRA2A (0.59) ADRA2AADRA2BADRA2CMLLT1PTGIR
SCHEMBL5660506 0.84 ADRA2A (0.68) LMNAADRA2AADRA2BADRA2CMLLT1
SCHEMBL5656678 0.83 ADRA2A (0.56) ADRA2AADRA2BADRA2CMLLT1PTGIR
SCHEMBL5657415 0.83 ADRA2A (0.59) ALDH1A1SMN1; SMN2MEN1KMT2ANAMPT
SCHEMBL5658659 0.83 ADRA2A (0.63) ADRA2AADRA2BADRA2CMLLT1PTGIR
SCHEMBL5657241 0.82 ADRA2A (0.60) ADRA2AADRA2BADRA2CMLLT1PTGIR
SCHEMBL5655412 0.82 NAMPT (0.59) ALDH1A1SMN1; SMN2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279498-B2 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC (US) 2007-10-09 US disclosed
US-7279498-B2 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC (US) 2007-10-09 US disclosed
US-7279498-B2 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC (US) 2007-10-09 US disclosed
US-6998414-B2 Substituted arylamides as IP antagonists ROCHE PALO ALTO LLC (US) 2006-02-14 US disclosed
US-20060004075-A1 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004075-A1 Substituted aryl amides as IP antagonists INSR, INSRR, GIPR ALDH1A1 2894/4885SMN1; SMN2 4654/4885MEN1 3607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.